Literature DB >> 26398710

Flavaglines Ameliorate Experimental Colitis and Protect Against Intestinal Epithelial Cell Apoptosis and Mitochondrial Dysfunction.

Jie Han1, Qian Zhao, Christine Basmadjian, Laurent Désaubry, Arianne L Theiss.   

Abstract

BACKGROUND: Flavaglines are a family of natural compounds shown to have anti-inflammatory and cytoprotective effects in neurons and cardiomyocytes. Flavaglines target prohibitins as ligands, which are scaffold proteins that regulate mitochondrial function, cell survival, and transcription. This study tested the therapeutic potential of flavaglines to promote intestinal epithelial cell homeostasis and to protect against a model of experimental colitis in which inflammation is driven by epithelial ulceration.
METHODS: Survival and homeostasis of Caco2-BBE and IEC-6 intestinal epithelial cell lines were measured during treatment with the flavaglines FL3 or FL37 alone and in combination with the proinflammatory cytokines tumor necrosis factor (TNF) α and interferon γ. Wild-type mice were intraperitoneally injected with 0.1 mg/kg FL3 or vehicle once daily for 4 days during dextran sodium sulfate-induced colitis to test the in vivo anti-inflammatory effect of FL3.
RESULTS: FL3 and FL37 increased basal Caco2-BBE and IEC-6 cell viability, decreased apoptosis, and decreased epithelial monolayer permeability. FL3 and FL37 inhibited TNFα- and interferon γ-induced nuclear factor kappa B and Cox2 expression, apoptosis, and increased permeability in Caco2-BBE cells. FL3 and FL37 protected against TNFα-induced mitochondrial superoxide generation by preserving respiratory chain complex I activity and prohibitin expression. p38-MAPK activation was essential for the protective effect of FL3 and FL37 on barrier permeability and mitochondrial-derived reactive oxygen species production during TNFα treatment. Mice administered FL3 during dextran sodium sulfate colitis exhibited increased colonic prohibitin expression and p38-MAPK activation, preserved barrier function, and less inflammation.
CONCLUSIONS: These results suggest that flavaglines exhibit therapeutic potential against colitis and preserve intestinal epithelial cell survival, mitochondrial function, and barrier integrity.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 26398710      PMCID: PMC5600465          DOI: 10.1097/MIB.0000000000000592

Source DB:  PubMed          Journal:  Inflamm Bowel Dis        ISSN: 1078-0998            Impact factor:   5.325


  44 in total

1.  Comparative proteomic studies on the pathogenesis of human ulcerative colitis.

Authors:  Sen-Yung Hsieh; Tsung-Chieh Shih; Chien-Yuh Yeh; Chun-Jung Lin; Yun-Ying Chou; Ying-Shiung Lee
Journal:  Proteomics       Date:  2006-10       Impact factor: 3.984

2.  A synthetic derivative of the natural product rocaglaol is a potent inhibitor of cytokine-mediated signaling and shows neuroprotective activity in vitro and in animal models of Parkinson's disease and traumatic brain injury.

Authors:  T Fahrig; I Gerlach; E Horváth
Journal:  Mol Pharmacol       Date:  2005-02-16       Impact factor: 4.436

Review 3.  Cytoprotection by the modulation of mitochondrial electron transport chain: the emerging role of mitochondrial STAT3.

Authors:  Karol Szczepanek; Qun Chen; Andrew C Larner; Edward J Lesnefsky
Journal:  Mitochondrion       Date:  2011-09-10       Impact factor: 4.160

Review 4.  Mucosal healing in inflammatory bowel diseases: a systematic review.

Authors:  Markus F Neurath; Simon P L Travis
Journal:  Gut       Date:  2012-07-27       Impact factor: 23.059

5.  Mitochondrial respiratory chain in the colonic mucosal of patients with ulcerative colitis.

Authors:  Karla G Sifroni; Carlos R Damiani; Cristhopher Stoffel; Mariane R Cardoso; Gabriela K Ferreira; Isabela C Jeremias; Gislaine T Rezin; Giselli Scaini; Patricia F Schuck; Felipe Dal-Pizzol; Emilio L Streck
Journal:  Mol Cell Biochem       Date:  2010-05-04       Impact factor: 3.396

6.  Synthetic analogue of rocaglaol displays a potent and selective cytotoxicity in cancer cells: involvement of apoptosis inducing factor and caspase-12.

Authors:  Frédéric Thuaud; Yohann Bernard; Gülen Türkeri; Ronan Dirr; Geneviève Aubert; Thierry Cresteil; Aurélie Baguet; Catherine Tomasetto; Yuri Svitkin; Nahum Sonenberg; Canan G Nebigil; Laurent Désaubry
Journal:  J Med Chem       Date:  2009-08-27       Impact factor: 7.446

7.  Dextran sulfate sodium (DSS)-induced colitis in mice.

Authors:  Benoit Chassaing; Jesse D Aitken; Madhu Malleshappa; Matam Vijay-Kumar
Journal:  Curr Protoc Immunol       Date:  2014-02-04

8.  Epithelial NEMO links innate immunity to chronic intestinal inflammation.

Authors:  Arianna Nenci; Christoph Becker; Andy Wullaert; Ralph Gareus; Geert van Loo; Silvio Danese; Marion Huth; Alexei Nikolaev; Clemens Neufert; Blair Madison; Deborah Gumucio; Markus F Neurath; Manolis Pasparakis
Journal:  Nature       Date:  2007-03-14       Impact factor: 49.962

Review 9.  Flavaglines: potent anticancer drugs that target prohibitins and the helicase eIF4A.

Authors:  Christine Basmadjian; Frédéric Thuaud; Nigel Ribeiro; Laurent Désaubry
Journal:  Future Med Chem       Date:  2013-12       Impact factor: 3.808

10.  Direct evidence for tumor necrosis factor-induced mitochondrial reactive oxygen intermediates and their involvement in cytotoxicity.

Authors:  V Goossens; J Grooten; K De Vos; W Fiers
Journal:  Proc Natl Acad Sci U S A       Date:  1995-08-29       Impact factor: 11.205

View more
  5 in total

1.  The Synthetic Small Molecule FL3 Combats Intestinal Tumorigenesis via Axin1-Mediated Inhibition of Wnt/β-Catenin Signaling.

Authors:  Dakota N Jackson; Kibrom M Alula; Yaritza Delgado-Deida; Redouane Tabti; Kevin Turner; Xuan Wang; K Venuprasad; Rhonda F Souza; Laurent Désaubry; Arianne L Theiss
Journal:  Cancer Res       Date:  2020-07-14       Impact factor: 12.701

Review 2.  Prohibitin ligands: a growing armamentarium to tackle cancers, osteoporosis, inflammatory, cardiac and neurological diseases.

Authors:  Dong Wang; Redouane Tabti; Sabria Elderwish; Hussein Abou-Hamdan; Amel Djehal; Peng Yu; Hajime Yurugi; Krishnaraj Rajalingam; Canan G Nebigil; Laurent Désaubry
Journal:  Cell Mol Life Sci       Date:  2020-02-15       Impact factor: 9.261

Review 3.  Vascular targeted nanotherapeutic approach for obesity treatment.

Authors:  Nicole Remaliah Samantha Sibuyi; Mervin Meyer; Martin Opiyo Onani; Amanda Skepu; Abram Madimabe Madiehe
Journal:  Int J Nanomedicine       Date:  2018-11-23

Review 4.  SFPH proteins as therapeutic targets for a myriad of diseases.

Authors:  Dong Wang; Redouane Tabti; Sabria Elderwish; Amel Djehal; Nora Chouha; Franck Pinot; Peng Yu; Canan G Nebigil; Laurent Désaubry
Journal:  Bioorg Med Chem Lett       Date:  2020-10-06       Impact factor: 2.823

5.  Deficiency of Sphingosine-1-Phosphate Reduces the Expression of Prohibitin and Causes β-Cell Impairment via Mitochondrial Dysregulation.

Authors:  Seok Woo Hong; Jinmi Lee; Hyemi Kwon; Se Eun Park; Eun Jung Rhee; Cheol Young Park; Ki Won Oh; Sung Woo Park; Won Young Lee
Journal:  Endocrinol Metab (Seoul)       Date:  2018-09
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.